Retinal Modulating Agents for Cis/Trans Ratio Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective solutions for treating or preventing diseases associated with endoplasmic reticulum stress, all-trans-retinal toxicity, and retinal thickness issues.
Innovation Solution
The use of retinal modulating agents, light absorbing substances, neural activity signaling agents or devices, and specific opsins or their derivatives to modulate the cis/trans ratio or concentration of retinal, thereby addressing the mentioned conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for endoplasmic reticulum stress diseases, then existing symptoms may be managed, but effective prevention and progression suppression remain unachieved
Solution Approach 1:
The patent applies parameter changes by modulating the cis/trans ratio of retinal and adjusting retinal concentration in the retina. By changing these biochemical parameters, the invention achieves preventive and progress-suppressing effects on endoplasmic reticulum stress diseases, transforming conventional symptom management into effective disease modification.
Solution Approach 2:
The patent uses retinal modulating agents as intermediary substances that mediate between light absorption and cellular signaling. These agents modulate the cis/trans ratio of retinal, thereby preventing endoplasmic reticulum stress and suppressing disease progression, filling the gap between conventional treatments and effective prevention.
2Reliability
If all-trans-retinal is used in the retina, then visual function is maintained, but toxicity and cell death occur
Solution Approach 1:
The patent changes the biochemical parameter of retinal configuration by modulating the cis/trans ratio. By increasing the proportion of cis-retinal and reducing all-trans-retinal accumulation, the invention maintains visual function while eliminating toxicity and preventing cell death.
Solution Approach 2:
The patent converts the harmful all-trans-retinal into beneficial cis-retinal through light absorption and isomerization processes. By utilizing the natural photoisomerization mechanism, the invention transforms the toxic all-trans form into the beneficial cis form, thereby eliminating toxicity while maintaining visual function.
3Shape
If retinal thickness is reduced, then atrophy progresses, but protection and suppression of atrophy remain unachieved
Solution Approach 1:
The patent changes the biochemical parameters of retinal metabolism by modulating the cis/trans ratio and concentration. These parameter changes trigger protective mechanisms that prevent retinal atrophy and maintain retinal thickness, transforming the progression of atrophy into a protected state.
Solution Approach 2:
The patent applies preliminary action by using retinal modulating agents to prevent atrophy before it fully develops. By maintaining appropriate retinal thickness through biochemical modulation, the invention provides advance protection against atrophic changes and preserves retinal structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions and methods demonstrate preventive, progress-suppressing, or therapeutic effects on diseases related to endoplasmic reticulum stress, all-trans-retinal toxicity, and retinal thickness, including protection against atrophy and improvement in retinal health.
Implementation Method 1
a light absorbing substance has preventive, progress-suppressing, or therapeutic effects on diseases associated with an endoplasmic reticulum stress
Implementation Method 2
opsins (rhodopsin), such as microbial opsins, that do not release retinal upon photoreception, protect retinal thickness or suppress atrophy
Data Source
AI summary
The present disclosure provides: a composition having an effect of preventing, suppressing the progress of, or treating a disease associated with an endoplasmic reticulum stress, such as a vesicle transport disorder, and a disorder such as cell death due to all-trans-retinal toxicity; and/or a composition for use in protecting the retina. A composition for use in treating or preventing a disease, disorder or symptom associated with an endoplasmic reticulum stress, the composition comprising a retinal modulating agent; a composition for use in treating or preventing a disease, disorder or symptom associated with all-trans-retinal, the composition comprising a retinal modulating agent; and a composition for use in protecting the retina, the composition comprising a retinal modulating agent, are provided. Use of a retinal modulating agent modulates a cis/trans ratio of retinal, thereby reducing the amount or concentration of all-trans-retinal resulting from photoreception of rhodopsin, where a therapeutic effect for diseases associated with endoplasmic reticulum stress, etc., or a disease associated with all-trans-retinal, and a protective effect for the retina can be expected.